Breast Cancer Research and Treatment

, Volume 29, Issue 1, pp 41–49 | Cite as

The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients

  • Stephen B Fox
  • Kenneth Smith
  • Justine Hollyer
  • Michael Greenall
  • Diana Hastrich
  • Adrian L Harris
Guest editor's introduction

Summary

Epidermal growth factor receptor (EGFR) and estrogen receptor (ER) were assayed by ligand binding in tumors from 370 patients with primary breast carcinoma with a median follow up of 18 months. Forty seven percent (175/370) and 57% (210/370) of tumors had >20 fmol/mg and >10 fmol/mg of EGFR and ER respectively. There was a highly significant inverse relationship between EGFR and ER (p=0.0032). There was also a significant association between EGFR and patient age (p=0.0006) but no correlation between EGFR and lymph node status, tumor grade, or tumor size (p=0.104, p=0.198, and p=0.085 respectively). In a univariate analysis of all patients, EGFR expression was not associated with a significant reduction in overall survival (OS). However, there was a significant decrease in relapse-free survival (RFS) and OS in node negative EGFR positive patients (p=0.03 and p=0.05 respectively). In a multivariate analysis (Cox proportional hazard model) of all patients, lymph node status was an independent prognostic indicator for OS and RFS (p<0.00005 and p=0.00005 respectively), ER status for RFS (p=0.0006), and EGFR (in the node negative model) for RFS (p=0.03). When all patients were stratified for EGFR and ER, there was a significant difference in RFS and OS such that EGFR positive and ER negative had the worst prognosis (p=0.0034 and p=0.005 respectively). A similar relationship was observed for OS in node negative patients (p=0.004) and for RFS in node positive patients (p=0.009). In a review of 3009 patients with follow-up, 11/16 series showed high EGFR was associated with shorter RFS or OS in univariate analysis, and 4 showed this in multivariate analysis. However, most series had inadequate follow-up time and most did not include multivariate analysis. This highlights the need for uniform criteria of reporting trials of prognostic factors.

Key words

breast neoplasms epidermal growth factor receptor prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris, AL: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150, 1991Google Scholar
  2. 2.
    Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398–1402, 1987Google Scholar
  3. 3.
    Klijn JG, Berns PM, Schmitz PI, Foekens JA: Epidermal growth factor receptor (EGF-R) in clinical breast cancer: Update 1993. Endocr Rev Monographs 1:171–174, 1993Google Scholar
  4. 4.
    Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3–17, 1992Google Scholar
  5. 5.
    Bolla M, Chedin M, Colonna M, Marron J, Rostaing PB, Chambaz E: Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur J Cancer 28A:1052–1054, 1992Google Scholar
  6. 6.
    Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppennberger U: Predictive value of EGF receptor in breast cancer. Lancet ii:1258, 1988Google Scholar
  7. 7.
    Foekens JA, Portengen H, van Putten Wl, Trapman AM, Reubi JC, Alexieva Figusch J, Klijn JG: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989Google Scholar
  8. 8.
    Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66:970–976, 1992Google Scholar
  9. 9.
    Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JR, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686–695, 1992Google Scholar
  10. 10.
    Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989Google Scholar
  11. 11.
    Hawkins R, Killen E, Whittle I, Jack W, Chetty U, Prescott R: Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance. Br J Cancer 63:553–560, 1991Google Scholar
  12. 12.
    Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blamey RW, Ellis IO: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385–389, 1990Google Scholar
  13. 13.
    Murray P, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes R: The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67:1408–1412, 1993Google Scholar
  14. 14.
    Macias A, Azavedo E, Hagerstrom T, Klintenberg C, Perez R, Skoog L: Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 7:459–464, 1987Google Scholar
  15. 15.
    Rios MA, Macias A, Perez R, Lage A, Skoog L: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173–176, 1988Google Scholar
  16. 16.
    Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977–980, 1991Google Scholar
  17. 17.
    Shrestha P, Yamada K, Wada T, Maeda S, Watatani M, Yasutomi M, Takagi H, Mori M: Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinico-pathological significance in breast cancer. Virchows Arch A Pathol Anat Histopathol 421:193–202, 1992Google Scholar
  18. 18.
    Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323–326, 1992Google Scholar
  19. 19.
    Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacene K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83–89, 1990Google Scholar
  20. 20.
    Koenders PG, Faverly D, Beex LV, Bruggink ED, Kienhuis CB, Benraad TJ: Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology. Eur J Cancer 28:693–697, 1992Google Scholar
  21. 21.
    Koenders P, Beex L, Kienhuis C, Kloppenborg P, Benraad T: Epidermal growth factor receptor in human breast cancer: a prospective study. Breast Cancer Res Treat 25:21–27, 1993Google Scholar
  22. 22.
    Barrett LP, Travers M, Luqmani Y, Coombes RC: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61:612–617, 1990Google Scholar
  23. 23.
    Elston C: Grading of invasive carcinoma of the breast.In: Page D, Anderson T (ed) Diagnostic Histopathology of the Breast. Churchill Livingstone, Edinburgh, 1987, pp 300–311Google Scholar
  24. 24.
    Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219, 1993Google Scholar
  25. 25.
    Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 71–85, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Stephen B Fox
    • 1
  • Kenneth Smith
    • 2
  • Justine Hollyer
    • 2
  • Michael Greenall
    • 3
  • Diana Hastrich
    • 4
  • Adrian L Harris
    • 2
  1. 1.Nuffield Department of PathologyUniversity of Oxford, John Radcliffe HospitalOxfordUK
  2. 2.ICRF Molecular Onclology LaboratoryUniversity of Oxford, John Radcliffe HospitalOxfordUK
  3. 3.Department of SurgeryUniversity of Oxford, John Radcliffe HospitalOxfordUK
  4. 4.Department of SurgeryUniversity of Bristol, Bristol Royal InfirmaryBristolUK

Personalised recommendations